Lymphadenectomy in upper tract urothelial carcinoma: Clinical insights and controversies (Review)
- Authors:
- Dihao Lv
- Yinglong Huang
- Haihao Li
- Shi Fu
- Chen Gong
- Chadanfeng Yang
- Jiansong Wang
- Haifeng Wang
- Zhiyong Tan
- Mingxia Ding
-
Affiliations: Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Institute of Urology, Kunming, Yunnan 650101, P.R. China - Published online on: August 8, 2025 https://doi.org/10.3892/or.2025.8970
- Article Number: 137
-
Copyright: © Lv et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Cowan NC, Dominguez-Escrig JL, Gontero P, Hugh Mostafid A, et al: European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 79:62–79. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS and Shariat SF: Urothelial carcinoma of the bladder and the upper tract: Disparate twins. J Urol. 189:1214–1221. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Peyrottes A, Ouzaid I, Califano G, Hermieu JF and Xylinas E: Neoadjuvant immunotherapy for muscle-invasive bladder cancer. Medicina (Kaunas). 57:7692021. View Article : Google Scholar : PubMed/NCBI | |
|
Giudici N, Bonne F, Blarer J, Minoli M, Krentel F and Seiler R: Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: A narrative review. Transl Androl Urol. 10:4036–4050. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD and Wood CG; Upper Tract Urothelial Carcinoma Collaboration The Upper Tract Urothelial Carcinoma Collaboration, : Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration. Cancer. 115:1224–1233. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Batata MA, Whitmore WF, Hilaris BS, Tokita N and Grabstald H: Primary carcinoma of the ureter: A prognostic study. Cancer. 35:1626–1632. 1975. View Article : Google Scholar : PubMed/NCBI | |
|
Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Cucchiara V, Tian Z, Shariat SF, Saad F, Longo N, Montorsi F, et al: Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma. Eur Urol Oncol. 4:792–801. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, et al: Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients. Eur J Cancer. 45:3291–3297. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo T and Tanabe K: Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract. Int J Urol. 19:710–721. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chappidi MR, Kates M, Johnson MH, Hahn NM, Bivalacqua TJ and Pierorazio PM: Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004–2012). Urol Oncol. 34:531.e15–531.e24. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, et al: A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology. 75:118–124. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF, Van Poppel H and Zigeuner R: Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol. 60:776–783. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Deuker M, Rosiello G, Stolzenbach LF, Martin T, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, et al: Sex- and age-related differences in the distribution of metastases in patients with upper urinary tract urothelial carcinoma. J Natl Compr Canc Netw. 19:534–540. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, et al: Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: Multi-institutional large retrospective study JCOG1110A. World J Urol. 35:1737–1744. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, et al: European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. 84:49–64. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, et al: Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline. J Urol. 209:1071–1081. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Akaza H, Koiso K and Niijima T: Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer. 59:1369–1375. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Matin SF, Sfakianos JP, Espiritu PN, Coleman JA and Spiess PE: Patterns of lymphatic metastases in upper tract urothelial carcinoma and proposed dissection templates. J Urol. 194:1567–1574. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo T, Hara I, Takagi T, Kodama Y, Hashimoto Y, Kobayashi H, Iizuka J, Omae K, Yoshida K and Tanabe K: Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. Int J Urol. 21:453–459. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen N, Fairey A, Izawa J, Black P, Tanguay S, et al: The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology. 79:840–845. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai TS, Jin L, Zhou Z, Liu X, Liu H, Chen W, Lu JY, Yao XD, Feng LM and Ye L: Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy. BMC cancer. 19:12072019. View Article : Google Scholar : PubMed/NCBI | |
|
Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, et al: Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): A phase 3, open-label, randomised controlled trial. Lancet. 395:1268–1277. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Ai JZ, Tan P, Lin TH, Jin X, Gong LN, Lei HR, Yang L and Wei Q: Pretreatment elevated fibrinogen level predicts worse oncologic outcomes in upper tract urothelial carcinoma. Asian J Androl. 22:177–183. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tan P, Shi M, Chen J, Xu H, Xie N, Xu H, Jiang Y, Ai JZ, Liu LR, Yang L and Wei Q: The preoperative serum cystatin-C as an independent prognostic factor for survival in upper tract urothelial carcinoma. Asian J Androl. 21:163–169. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y and Kihara K: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 100:269–273. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Tan P, Ai J, Huang Y, Lin T, Yang L and Wei Q: Prognostic impact of preoperative albumin-globulin ratio on oncologic outcomes in upper tract urothelial carcinoma treated with radical nephroureterectomy. Clin Genitourin Cancer. 16:e1059–e1068. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, Shariat SF, et al: Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 191:316–322. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, et al: Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 35:121–130. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nakazawa H, Ito F and Tanabe K: Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival. Int J Urol. 17:848–854. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H and Tanabe K: Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol. 178:1212–1217. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo T, Hara I, Takagi T, Kodama Y, Hashimoto Y, Kobayashi H, Iizuka J, Omae K, Ikezawa E, Yoshida K and Tanabe K: Possible role of template-based lymphadenectomy in reducing the risk of regional node recurrence after nephroureterectomy in patients with renal pelvic cancer. Jpn J Clin Oncol. 44:1233–1238. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Burger M, Shariat SF, Fritsche HM, Martinez-Salamanca JI, Matsumoto K, Chromecki TF, Ficarra V, Kassouf W, Seitz C, Pycha A, et al: No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: A retrospective international, multi-institutional study. World J Urol. 29:465–472. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Duquesne I, Ouzaid I, Loriot Y, Moschini M and Xylinas E: Lymphadenectomy for upper tract urothelial carcinoma: A systematic review. J Clin Med. 8:11902019. View Article : Google Scholar : PubMed/NCBI | |
|
Stein JP, Cai J, Groshen S and Skinner DG: Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: Concept of lymph node density. J Urol. 170:35–41. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bolenz C, Shariat SF, Fernández MI, Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, et al: Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: Value of lymph-node density. BJU Int. 103:302–306. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rao SR, Correa JJ, Sexton WJ, Pow-Sang JM, Dickinson SI, Lin HY and Spiess PE: Prospective clinical trial of the feasibility and safety of modified retroperitoneal lymph node dissection at time of nephroureterectomy for upper tract urothelial carcinoma. BJU Int. 110:E475–E480. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Abe T, Takada N, Matsumoto R, Osawa T, Sazawa A, Maruyama S, Tsuchiya K, Harabayashi T, Minami K, Nagamori S, et al: Outcome of regional lymphadenectomy in accordance with primary tumor location on laparoscopic nephroureterectomy for urothelial carcinoma of the upper urinary tract: A prospective study. J Endourol. 29:304–309. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lu H, Liang Y, Guan B, Shi Y, Gong Y, Li J, Kong W, Liu J, Fang D, Liu L, et al: Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma. Theranostics. 10:4323–4333. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W and Ficarra V: Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer. 110:1715–1722. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Secin FP, Koppie TM, Salamanca JI, Bokhari S, Raj GV, Olgac S, Martignoni G, Patard JJ, Artibani W and Ficarra V: Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. Int J Urol. 14:26–32. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Roscigno M, Cozzarini C, Bertini R, Scattoni V, Freschi M, Da Pozzo LF, Briganti A, Gallina A, Capitanio U, Colombo R, et al: Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol. 53:794–802. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cho KS, Choi HM, Koo K, Park SJ, Rha KH, Choi YD, Chung BH, Cho NH, Yang SC and Hong SJ: Clinical significance of lymph node dissection in patients with muscle-invasive upper urinary tract transitional cell carcinoma treated with nephroureterectomy. J Korean Med Sci. 24:674–678. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ouzzane A, Colin P, Ghoneim TP, Zerbib M, De La Taille A, Audenet F, Saint F, Hoarau N, Adam E, Azemar MD, et al: The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World J Urol. 31:189–197. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Abe T, Shinohara N, Muranaka M, Sazawa A, Maruyama S, Osawa T, Harabayashi T, Kubota K, Matsuno Y, Shibata T, et al: Role of lymph node dissection in the treatment of urothelial carcinoma of the upper urinary tract: multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes. Eur J Surg Oncol. 36:1085–1091. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, et al: Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 181:2482–2489. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, et al: Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Expanded efficacy from checkmate 274. J Clin Oncol. 43:15–21. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Abufaraj M, Li R, Meeks J and Shariat SF: Cytoreductive surgery in patients with urothelial bladder cancer. Eur Urol Focus. 9:278–279. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, et al: Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Urol Oncol. 40:105.e19–105.e26. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Jung H, Giusti G, Fajkovic H, Herrmann T, Jones R, Straub M, Baard J, Osther PJS and Brehmer M: Consultation on UTUC, Stockholm 2018: Aspects of treatment. World J Urol. 37:2279–2287. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R and Sonpavde G: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 23:406–410. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, et al: Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 384:2102–2114. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Li X, Liu Y, Fang J, Zhang X and Xiao K: Can American Joint Committee on Cancer prognostic groups be individualized in patients undergoing surgery for Stage IV invasive upper tract Urothelial Carcinoma? J Cancer. 12:2023–2029. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Abdel-Rahman O: Revisiting the prognostic heterogeneity of AJCC Stage IV carcinomas of the upper urinary tract. Clin Genitourin Cancer. 16:e859–e865. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Flaig TW, Spiess PE, Chair V, Abern M, Agarwal N and Buyyounouski MK: NCCN Guidelines Version 3.2023 Bladder Cancer. National Comprehensive Cancer Network. Available from:. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417 | |
|
Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Gontero P, et al: Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the European association of urology guidelines panel on non-muscle-invasive bladder cancer. Eur Urol Focus. 5:224–241. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Brausi MA, Gavioli M, De Luca G, Verrini G, Peracchia G, Simonini G and Viola M: Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: Impact on survival. Eur Urol. 52:1414–1418. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Matsumoto R, Abe T, Takada N, Minami K, Harabayashi T, Nagamori S, Hatanaka KC, Yamashiro K, Kikuchi H, Osawa T, et al: Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up study. Urol Oncol. 38:933.e13–933.e18. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Furuse H, Matsushita Y, Yajima T, Kato T, Suzuki T, Matsumoto R, Motoyama D, Sugiyama T, Otsuka A and Ozono S: Systematic regional lymph node dissection for upper tract urothelial carcinoma improves patient survival. Jpn J Clin Oncol. 47:239–246. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda M, Matsumoto K, Sakaguchi K, Ishii D, Tabata KI, Kurosawa K, Urakami S, Okaneya T and Iwamura M: Effect of lymphadenectomy during radical nephroureterectomy in locally advanced upper tract urothelial carcinoma. Clin Genitourin Cancer. 15:556–562. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yoo S, You D, Jeong IG, Hong B, Hong JH, Ahn H and Kim CS: Does lymph node dissection during nephroureterectomy affect oncological outcomes in upper tract urothelial carcinoma patients without suspicious lymph node metastasis on preoperative imaging studies? World J Urol. 35:665–673. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Inokuchi J, Eto M, Hara T, Fujimoto H, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T and Ohyama C; Cancer Registration Committee of the Japanese Urological Association, : Impact of lymph node dissection on clinical outcomes during nephroureterectomy in patients with clinically node-negative upper urinary tract urothelial cancer: Subanalysis of a multi-institutional nationwide case series of the Japanese Urological Association. Jpn J Clin Oncol. 47:652–659. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pearce SM, Pariser JJ, Patel SG, Steinberg GD, Shalhav AL and Smith ND: The effect of surgical approach on performance of lymphadenectomy and perioperative morbidity for radical nephroureterectomy. Urol Oncol. 34:121.e15–21. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD, Sankin AI, Sfakianos JP, Cha EK, Dalbagni G and Coleman JA: Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 35:151.e9–151.e15. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dong F, Xu T, Wang X, Shen Y, Zhang X, Chen S, Zhong S, Zhang M and Ding Q: Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: A population-based, propensity score-matched study. Int J Clin Oncol. 24:296–305. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM and Matin SF: Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 98:1176–1180. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li CC, Chang CH, Huang CP, Hong JH, Huang CY, Chen IA, Lin JT, Lo CW, Yu CC, Tseng JS, et al: Comparing oncological outcomes and surgical complications of hand-assisted, laparoscopic and robotic nephroureterectomy for upper tract urothelial carcinoma. Front Oncol. 11:7314602021. View Article : Google Scholar : PubMed/NCBI | |
|
Clements MB, Krupski TL and Culp SH: Robotic-assisted surgery for upper tract urothelial carcinoma: A comparative survival analysis. Ann Surg Oncol. 25:2550–2562. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, Maclennan S, N'dow J, Babjuk M, Comperat E, et al: Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: An European association of urology guidelines systematic review. Eur Urol Focus. 5:205–223. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ishiyama Y, Kondo T, Kubota S, Shimada K, Yoshida K, Takagi T, Iizuka J and Tanabe K: Therapeutic benefit of lymphadenectomy for older patients with urothelial carcinoma of the upper urinary tract: A propensity score matching study. Jpn J Clin Oncol. 51:802–809. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Dindo D, Demartines N and Clavien PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240:205–213. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Blom JH, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L and Sylvester R; EORTC Genitourinary Tract Cancer Group, : Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 55:28–34. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo T, Takagi T and Tanabe K: Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. World J Clin Oncol. 6:237–251. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M and Abufaraj M: Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): A systematic review and meta-analysis. World J Urol. 38:1165–1175. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Millán-Rodríguez F, Palou J, de la Torre-Holguera P, Vayreda-Martija JM, Villavicencio-Mavrich H and Vicente Rodríguez J: Conventional CT signs in staging transitional cell tumors of the upper urinary tract. Eur Urol. 35:318–322. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Pallauf M, D'Andrea D, König F, Laukhtina E, Yanagisawa T, Rouprêt M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, et al: Diagnostic accuracy of clinical lymph node staging for upper tract urothelial cancer patients: A multicenter, retrospective, observational study. J Urol. 209:515–524. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, et al: Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol. 62:677–684. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Zubaidi M, Viswambaram P, McCombie S, Liow E, Lenzo N, Ferguson T, Redfern AD, Gauci R and Hayne D: 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): Protocol for a phase I trial of a novel staging modality for urothelial carcinoma. BMJ Open. 12:e0604782022. View Article : Google Scholar : PubMed/NCBI | |
|
Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M, Spiess PE, Briganti A, et al: Diagnostic Value of 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma. Eur Urol Oncol. 3:73–79. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zattoni F, Incerti E, Colicchia M, Castellucci P, Panareo S, Picchio M, Fallanca F, Briganti A, Moschini M, Gallina A, et al: Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: A retrospective, multicenter study. Abdom Radiol (NY). 43:2391–2399. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Soubra A, Hayward D, Dahm P, Goldfarb R, Froehlich J, Jha G and Konety BR: The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: A single-institution study and a systematic review with meta-analysis. World J Urol. 34:1229–1237. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Aydh A, Abufaraj M, Mori K, Quhal F, Pradere B, Motlagh RS, Mostafaei H, Karakiewicz PI and Shariat SF: Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: A systematic review. Arab J Urol. 19:59–66. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N and Bouchelouche K: Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: Correlation with histopathology. Scand J Urol Nephrol. 45:122–128. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Asai S, Fukumoto T, Tanji N, Miura N, Miyagawa M, Nishimura K, Yanagihara Y, Shirato A, Miyauchi Y, Kikugawa T and Yokoyama M: Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma. Int J Clin Oncol. 20:1042–1047. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, et al: Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in upper tract urothelial carcinoma: Impact on detection of metastases and patient management. Urol Int. 96:65–72. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Takayanagi A, Takahashi A, Yorozuya W, Okabe K, Kaji T and Takagi Y: The usefulness of positron emission tomography/computed tomography in the diagnosis of metastasis in patients with urothelial carcinoma. Nihon Hinyokika Gakkai Zasshi. 113:51–55. 2022.(In Japanese). PubMed/NCBI | |
|
Galili U: Cancer immunotherapy by anti-gal-mediated in situ conversion of tumors into autologous vaccines. The Natural Anti-gal Antibody as Foe Turned Friend in Medicine, . 1st edition. Elsevier; Amsterdam: pp. 171–198. 2018 | |
|
Nayak B, Dogra PN, Naswa N and Kumar R: Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: Prospective evaluation of a novel technique. Eur J Nucl Med Mol Imaging. 40:386–393. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jana S and Blaufox MD: Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. 36:51–72. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sassa N, Kato K, Abe S, Iwano S, Ito S, Ikeda M, Shimamoto K, Yamamoto S, Yamamoto T, Gotoh M and Naganawa S: Evaluation of 11C-choline PET/CT for primary diagnosis and staging of urothelial carcinoma of the upper urinary tract: A pilot study. Eur J Nucl Med Mol Imaging. 41:2232–2241. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Polom W, Cytawa W, Polom A, Frankiewicz M, Szurowska E, Lass P and Matuszewski M: Challenging visualization of sentinel lymph nodes in upper urinary tract urothelial carcinoma. J Clin Med. 10:54652021. View Article : Google Scholar : PubMed/NCBI | |
|
Lebastchi AH, Gupta N, DiBianco JM, Piert M, Davenport MS, Ahdoot MA, Gurram S, Bloom JB, Gomella PT, Mehralivand S, et al: Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: A critical review. Transl Androl Urol. 9:1415–1427. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fortuin AS, Smeenk RJ, Meijer HJ, Witjes AJ and Barentsz JO: Lymphotropic nanoparticle-enhanced MRI in prostate cancer: Value and therapeutic potential. Curr Urol Rep. 15:3892014. View Article : Google Scholar : PubMed/NCBI | |
|
Birkhäuser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A and Thoeny HC: Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol. 64:953–960. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Caglic I and Barrett T: Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer. Transl Androl Urol. 7:814–823. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Woo S, Suh CH, Kim SY, Cho JY and Kim SH: The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: An updated systematic review and diagnostic meta-analysis. AJR Am J Roentgenol. 210:W95–W109. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shamis SAK, Edwards J and McMillan DC: The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: Systematic review and meta-analysis. Diagn Pathol. 18:462023. View Article : Google Scholar : PubMed/NCBI | |
|
Venkat S, Khan AI, Lewicki PJ, Borregales L and Scherr DS: Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma. Urol Oncol. 40:108.e11–108.e17. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li WM, Chan TC, Huang SK, Wu WJ, Ke HL, Liang PI, Wei YC, Shiue YL and Li CF: Prognostic utility of FBLN2 expression in patients with urothelial carcinoma. Front Oncol. 10:5703402020. View Article : Google Scholar : PubMed/NCBI | |
|
Ibrahim AM, Sabet S, El-Ghor AA, Kamel N, Anis SE, Morris JS and Stein T: Fibulin-2 is required for basement membrane integrity of mammary epithelium. Sci Rep. 8:141392018. View Article : Google Scholar : PubMed/NCBI | |
|
de Vega S, Iwamoto T and Yamada Y: Fibulins: Multiple roles in matrix structures and tissue functions. Cell Mol Life Sci. 66:1890–1902. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Argraves WS, Greene LM, Cooley MA and Gallagher WM: Fibulins: Physiological and disease perspectives. EMBO Rep. 4:1127–1131. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Timpl R, Sasaki T, Kostka G and Chu ML: Fibulins: A versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol. 4:479–489. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, et al: Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One. 8:e670542013. View Article : Google Scholar : PubMed/NCBI | |
|
Senapati S, Gnanapragassam VS, Moniaux N, Momi N and Batra SK: Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene. 31:3346–3356. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mohammad T, Arif K, Alajmi MF, Hussain A, Islam A, Rehman MT and Hassan I: Identification of high-affinity inhibitors of pyruvate dehydrogenase kinase-3: Towards therapeutic management of cancer. J Biomol Struct Dyn. 39:586–594. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu J, Zheng G, Xu H, Jin X, Tang T and Wang X: Expression and prognostic significance of pyruvate dehydrogenase kinase 1 in bladder urothelial carcinoma. Virchows Arch. 477:637–649. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Woolbright BL, Choudhary D, Mikhalyuk A, Trammel C, Shanmugam S, Abbott E, Pilbeam CC and Taylor JA III: The role of pyruvate dehydrogenase kinase-4 (PDK4) in bladder cancer and chemoresistance. Mol Cancer Ther. 17:2004–2012. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo YH, Chan TC, Lai HY, Chen TJ, Wu LC, Hsing CH and Li CF: Overexpression of pyruvate dehydrogenase kinase-3 predicts poor prognosis in urothelial carcinoma. Front Oncol. 11:7491422021. View Article : Google Scholar : PubMed/NCBI | |
|
Posey KL, Coustry F and Hecht JT: Cartilage oligomeric matrix protein: COMPopathies and beyond. Matrix Biol. 71-72:161–173. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Englund E, Bartoschek M, Reitsma B, Jacobsson L, Escudero-Esparza A, Orimo A, Leandersson K, Hagerling C, Aspberg A, Storm P, et al: Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer. Oncogene. 35:5585–5596. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu TT, Liu XS, Zhang M, Liu XN, Zhu FX, Zhu FM, Ouyang SW, Li SB, Song CL, Sun HM, et al: Cartilage oligomeric matrix protein is a prognostic factor and biomarker of colon cancer and promotes cell proliferation by activating the Akt pathway. J Cancer Res Clin Oncol. 144:1049–1063. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK and Dalekos GN: Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol. 7:1875–1883. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo YH, Lai HY, Chan TC, Hsing CH, Huang SK, Hsieh KL, Chen TJ, Li WS, Lu JC and Li CF: Upregulation of cartilage oligomeric matrix protein predicts poor prognosis in urothelial carcinoma. Onco Targets Ther. 15:727–740. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li WM, Ke HL, Kuo YH, Lai HY, Chan TC, Hsing CH, Hsieh KL, Li WS, Chen TJ, Wei YC, et al: High MT2A expression predicts worse prognosis in patients with urothelial carcinoma. Oncology. 100:485–497. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Nishikawa M, Miyake H, Kurahashi T and Fujisawa M: Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy. Int J Clin Oncol. 23:151–157. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mori K, Janisch F, Mostafaei H, Kimura S, Lysenko I, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, et al: Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. Urol Oncol. 38:601.e17–601.e24. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Diao F, Ye Z, Zhang X, Zhai E, Ren H, Li T, Wu H, He Y, Cai S and Chen J: Prognostic value of systemic immune-inflammation index in patients with gastric cancer. Chin J Cancer. 36:752017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Chen B, Wang L, Wang R and Yang X: Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis. Medicine (Baltimore). 98:e137882019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Wang C, Wang J, Huang X and Cheng Y: A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 143:2077–2086. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jan HC, Wu KY, Tai TY, Weng HY, Yang WH, Ou CH and Hu CY: The systemic immune-inflammation index (SII) increases the prognostic significance of lymphovascular invasion in upper tract urothelial carcinoma after radical nephroureterectomy. Cancer Manag Res. 14:3139–3149. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi S, Ito M, Takemura K, Suzuki H, Yonese I and Koga F: Preoperative models incorporating the systemic immune-inflammation index for predicting prognosis and muscle invasion in patients with non-metastatic upper tract urothelial carcinoma. Int J Clin Oncol. 27:574–584. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.PubMed/NCBI | |
|
Therkildsen C, Eriksson P, Höglund M, Jönsson M, Sjödahl G, Nilbert M and Liedberg F: Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol. 12:1286–1295. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pradere B, Lotan Y and Roupret M: Lynch syndrome in upper tract urothelial carcinoma: Significance, screening, and surveillance. Curr Opin Urol. 27:48–55. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Audenet F, Colin P, Yates DR, Ouzzane A, Pignot G, Long JA, Soulie M, Phé V, Bensadoun H, Guy L, et al: A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: Proposal of patient-specific risk identification tool. BJU Int. 110:E583–E589. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ju JY, Mills AM, Mahadevan MS, Fan J, Culp SH, Thomas MH and Cathro HP: Universal lynch syndrome screening should be performed in all upper tract urothelial carcinomas. Am J Surg Pathol. 42:1549–1555. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gayhart MG, Johnson N, Paul A, Quillin JM, Hampton LJ, Idowu MO and Smith SC: Universal mismatch repair protein screening in upper tract urothelial carcinoma. Am J Clin Pathol. 154:792–801. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rasmussen M, Madsen MG and Therkildsen C: Immunohistochemical screening of upper tract urothelial carcinomas for lynch syndrome diagnostics: A systematic review. Urology. 165:44–53. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ, et al: Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 38:2658–2666. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al: Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, et al: Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 381:338–348. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y, et al: Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell. 39:793–809.e8. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, et al: Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int. 114:733–740. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, et al: Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol. 70:1052–1068. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T and Bellmunt J: Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: A 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 79:635–654. 2021. View Article : Google Scholar : PubMed/NCBI |
